VRTX241220C375000
- 0.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals (VRTX.US) pain relief medication faces the "placebo effect" and has its rating downgraded by Oppenheimer.
Vertex Downgraded to Perform by Oppenheimer
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
Vertex Pharmaceuticals Analyst Ratings
Wolfe Research Cuts Vertex Pharmaceuticals' Price Target to $531 From $538
BMO Capital Cuts Price Target on Vertex Pharmaceuticals to $520 From $566
Vertex Pharmaceuticals Analyst Ratings
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $494
Stifel Adjusts Price Target on Vertex Pharmaceuticals to $494 From $490, Maintains Hold Rating
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $525
Jefferies follows JPMorgan's call on Vertex Pharmaceuticals (VRTX.US) and raises the target price to $550.
Vertex Pharmaceuticals Raised to Buy From Hold by Jefferies
Vertex Pharmaceuticals Analyst Ratings
Jefferies Upgrades Vertex Pharmaceuticals(VRTX.US) to Buy Rating, Raises Target Price to $550
Evercore ISI Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575